These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 24890318)
21. Targeting the androgen receptor pathway in prostate cancer. Chen Y; Sawyers CL; Scher HI Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639 [TBL] [Abstract][Full Text] [Related]
22. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127 [TBL] [Abstract][Full Text] [Related]
23. Androgen receptor‑mediated upregulation of quaking affects androgen receptor‑related prostate cancer development and anti‑androgen receptor therapy. Zhang K; Yan F; Lei X; Wei D; Lu H; Zhu Z; Xiang A; Ye Z; Wang L; Zheng W; Li X; Yuan J; Lu Z; Yuan J Mol Med Rep; 2018 Jun; 17(6):8203-8211. PubMed ID: 29658587 [TBL] [Abstract][Full Text] [Related]
25. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T; J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218 [TBL] [Abstract][Full Text] [Related]
26. Targeting the androgen receptor. Friedlander TW; Ryan CJ Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523 [TBL] [Abstract][Full Text] [Related]
27. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214 [TBL] [Abstract][Full Text] [Related]
28. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines. Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490 [TBL] [Abstract][Full Text] [Related]